Dr. Chery is currently a full-time gene therapy product reviewer (Chemistry, Manufacturing, and Controls) at the FDA. She works on numerous gene therapy regulatory files and participates in preapproval inspections of manufacturing facilities. She is actively engaged in FDA working groups and has contributed to regulatory guidance documents for gene therapy products. She was on the BLA review team for the first FDA approved treatment to use a novel genome editing technology: CASGEVY, a gene therapy for sickle cell treatment.
Prior to the FDA, Dr. Chery did post-doctoral research at Harvard Medical School/Massachusetts General Hospital and Dana Farber Cancer Institute. Her postdoctoral research identified small molecules with therapeutic potential for Ebola and developed a gene therapy using genome editing and viral vector technologies. Dr. Chery received her PhD in Molecular Biology, Cell Biology, and Biochemistry from Brown University. Her PhD thesis characterized a previously unstudied zinc finger protein identified by the lab, elucidating its function in DNA packaging and regulation of acetylation marks implicated in cancers.